Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway
نویسندگان
چکیده
منابع مشابه
Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway
p53 is a frequent target for mutation in human tumors, and mutant p53 proteins can actively contribute to tumorigenesis. We employed a three-dimensional culture model in which nonmalignant breast epithelial cells form spheroids reminiscent of acinar structures found in vivo, whereas breast cancer cells display highly disorganized morphology. We found that mutant p53 depletion is sufficient to p...
متن کاملEstrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway
The Cancer Genome Atlas (TCGA) data indicate that high MDM2 expression correlates with all subtypes of breast cancer. Overexpression of MDM2 drives breast oncogenesis in the presence of wild-type or mutant p53 (mtp53). Importantly, estrogen-receptor positive (ER+) breast cancers overexpress MDM2 and estrogen mediates this expression. We previously demonstrated that this estrogen-MDM2 axis activ...
متن کاملThe mevalonate pathway regulates primitive streak formation via protein farnesylation
The primitive streak in peri-implantation embryos forms the mesoderm and endoderm and controls cell differentiation. The metabolic cues regulating primitive streak formation remain largely unknown. Here we utilised a mouse embryonic stem (ES) cell differentiation system and a library of well-characterised drugs to identify these metabolic factors. We found that statins, which inhibit the mevalo...
متن کاملTumor surveillance via the ARF-p53 pathway.
The retinoblastoma (Rb) and p53 genes are not essential for completion of the cell division cycle, but disruption of their functions is central to the life history of most, if not all, cancer cells (for review, see Weinberg 1995; Sherr 1996; Levine 1997). Surprisingly, Rb and p53 are themselves regulated by two proteins encoded by a single genetic locus, INK4a/ARF, the products of which, p16 an...
متن کاملZoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
It is unknown whether zoledronic acid (ZA) at clinically relevant doses is active against tumours not located in bone. Mice transgenic for the activated ErbB-2 oncogene were treated with a cumulative number of doses equivalent to that recommended in human beings. A significant increase in tumour-free and overall survival was observed in mice treated with ZA. At clinically compatible concentrati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cell
سال: 2012
ISSN: 0092-8674
DOI: 10.1016/j.cell.2011.12.017